| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4408 | 2018 |
| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England Journal of Medicine 369 (2), 134-144, 2013 | 4196 | 2013 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3096 | 2012 |
| Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ... Cell 161 (7), 1681-1696, 2015 | 2674 | 2015 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 2582 | 2018 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2574 | 2012 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2446 | 2018 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2155 | 2018 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2090 | 2014 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2021 | 2018 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1583 | 2018 |
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823, 2017 | 1496 | 2017 |
| Whole-genome landscapes of major melanoma subtypes NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ... Nature 545 (7653), 175-180, 2017 | 1271 | 2017 |
| Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma GV Long, AM Menzies, AM Nagrial, LE Haydu, AL Hamilton, GJ Mann, ... Journal of Clinical Oncology 29 (10), 1239-1246, 2011 | 1270 | 2011 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1095 | 2016 |
| Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery 4 (1), 80-93, 2014 | 1052 | 2014 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1019 | 2012 |
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ... The Lancet 379 (9829), 1893-1901, 2012 | 1006 | 2012 |
| Cutaneous melanoma JF Thompson, RA Scolyer, RF Kefford The Lancet 365 (9460), 687-701, 2005 | 994 | 2005 |
| Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 911 | 2018 |
